Posted by Michael Wonder on 04 Feb 2025
Comanche Biopharma awarded Innovation passport designation by the UK Innovative Licensing and Access Pathway Steering Group for CBP-4888, an investigational siRNA drug candidate for the treatment of sFlt1-mediated preterm pre-eclampsia
30 January 2025 - A novel investigational drug candidate, CBP-4888 leverages the precise targeting ability of siRNAs to downregulate sFlt1 in the placenta, a key pathogenic mediator of pre-eclampsia.
Comanche Biopharma today announced that the UK Innovative Licensing and Access Pathway (ILAP) Steering Group has awarded an Innovation Passport to CBP-4888, Comanche Biopharma’s investigational drug candidate for the treatment of sFlt1-mediated preterm pre-eclampsia.
